Rivaroxaban Superior to Enoxaparin in Non-Major Orthopaedic Surgery for Prevention of Major VTE
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic SurgeryN Engl J Med. 2020 May 14;382(20):1916-1925.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Three thousand six hundred and four patients scheduled for a non-major lower limb surgery were randomized to receive oral rivaroxaban or subcutaneous enoxaparin for the prevention of major venous thromboembolic events. The primary outcome of interest was major venous thromboembolism, which was a composite of the incidence of symptomatic distal or proximal deep vein thrombosis, pulmonary embolism a...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE